Retatrutide Demonstrates Efficacy in Obesity and Type 2 Diabetes Phase 3 Trial

The TRIUMPH-2 Phase 3 trial, published in The Lancet, reported that retatrutide, a triple hormone receptor agonist, significantly improved bodyweight and glycemic control in adults with obesity and type 2 diabetes. The drug's safety profile was consistent with other GLP-1 receptor agonists, primarily showing gastrointestinal side effects. These positive results suggest a potential new therapeutic option for managing these widespread conditions.